

03/31/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 71007/137/USGO

In re patent application of
 Apurba BHATTACHARJEE et al.
 Serial No. 08/230,402
 Filed: April 20, 1994
 For: VACCINE AGAINST GRAM-NEGATIVE BACTERIAL INFECTIONS

Group Art Unit: 1802
 Examiner: H. Sidberry
 BOX AF

15/B
 B9.1
 4/25/97
 (NE)

AMENDMENT AND REQUEST FOR RECONSIDERATION
UNDER 37 C.F.R. § 1.116

Assistant Commissioner for Patents
 Washington, D.C. 20231
 BOX AF

RECEIVED
 APR 23 1997
 GROUP 1800

Sir:

Responsive to an Office Action mailed October 29, 1996, the period for response having been extended to March 29 by the accompanying petition and fee, applicants submit the following claim cancellation and amendments, declarations from experts, and remarks.

IN THE CLAIMS:

Please amend the claims as follows:

Subj D

1. (Amended) A vaccine, effective in actively or passively immunizing a subject against infection by heterologous Gram-negative bacteria or against lipopolysaccharide (LPS) endotoxin-mediated pathology by the production of an antibody, comprising a non-covalent complex between (i) purified, detoxified LPS endotoxin devoid of O-oligosaccharide side chains derived from *E. coli J5 strain* and (ii) a purified, detoxified outer membrane protein (OMP) derived from *N. meningitidis*, wherein the antibody produced by said vaccine is not bacteriocidal.

Scop

not proper amendment